Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily

In a randomized, phase III trial of nilotinib versus imatinib in patients with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia in chronic phase, more patients had suboptimal response or treatment failure on front-line imatinib than on nilotinib. Patients with suboptimal res...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Hughes, Timothy P., Hochhaus, Andreas, Kantarjian, Hagop M., Cervantes, Francisco, Guilhot, François, Niederwieser, Dietger, le Coutre, Philipp D., Rosti, Gianantonio, Ossenkoppele, Gert, Lobo, Clarisse, Shibayama, Hirohiko, Fan, Xiaolin, Menssen, Hans D., Kemp, Charisse, Larson, Richard A., Saglio, Giuseppe
Formato: Artigo
Idioma:Inglês
Publicado em: Ferrata Storti Foundation 2014
Assuntos:
Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4077082/
https://ncbi.nlm.nih.gov/pubmed/24532039
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2013.091272
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados